Optimal Glycemic Control, Pre-eclampsia, and Gestational Hypertension in Women With Type 1 Diabetes in the Diabetes and Pre-eclampsia Intervention Trial
Open Access
- 16 July 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (8), 1683-1688
- https://doi.org/10.2337/dc11-0244
Abstract
OBJECTIVE: To assess the relationship between glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes. RESEARCH DESIGN AND METHODS: Pregnancy outcome (pre-eclampsia or gestational hypertension) was assessed prospectively in 749 women from the randomized controlled Diabetes and Pre-eclampsia Intervention Trial (DAPIT). HbA1c (A1C) values were available up to 6 months before pregnancy (n = 542), at the first antenatal visit (median 9 weeks) (n = 721), at 26 weeks’ gestation (n = 592), and at 34 weeks’ gestation (n = 519) and were categorized as optimal (<6.1%: referent), good (6.1–6.9%), moderate (7.0–7.9%), and poor (≥8.0%) glycemic control, respectively. RESULTS: Pre-eclampsia and gestational hypertension developed in 17 and 11% of pregnancies, respectively. Women who developed pre-eclampsia had significantly higher A1C values before and during pregnancy compared with women who did not develop pre-eclampsia (P < 0.05, respectively). In early pregnancy, A1C ≥8.0% was associated with a significantly increased risk of pre-eclampsia (odds ratio 3.68 [95% CI 1.17–11.6]) compared with optimal control. At 26 weeks’ gestation, A1C values ≥6.1% (good: 2.09 [1.03–4.21]; moderate: 3.20 [1.47–7.00]; and poor: 3.81 [1.30–11.1]) and at 34 weeks’ gestation A1C values ≥7.0% (moderate: 3.27 [1.31–8.20] and poor: 8.01 [2.04–31.5]) significantly increased the risk of pre-eclampsia compared with optimal control. The adjusted odds ratios for pre-eclampsia for each 1% decrement in A1C before pregnancy, at the first antenatal visit, at 26 weeks’ gestation, and at 34 weeks’ gestation were 0.88 (0.75–1.03), 0.75 (0.64–0.88), 0.57 (0.42–0.78), and 0.47 (0.31–0.70), respectively. Glycemic control was not significantly associated with gestational hypertension. CONCLUSIONS: Women who developed pre-eclampsia had significantly higher A1C values before and during pregnancy. These data suggest that optimal glycemic control both early and throughout pregnancy may reduce the risk of pre-eclampsia in women with type 1 diabetes.Keywords
This publication has 24 references indexed in Scilit:
- Hypertension in diabetic pregnancy: impact and long-term outlookBest Practice & Research Clinical Endocrinology & Metabolism, 2010
- Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trialThe Lancet, 2010
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2010
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- Microalbuminuria, Preeclampsia, and Preterm Delivery in Pregnant Women With Type 1 DiabetesDiabetes Care, 2009
- Obstetric and Perinatal Outcomes in Type 1 Diabetic PregnanciesDiabetes Care, 2009
- The Global Impact of Pre-eclampsia and EclampsiaSeminars in Perinatology, 2009
- Glycaemic control throughout pregnancy and risk of pre‐eclampsia in women with type I diabetesBJOG: An International Journal of Obstetrics and Gynaecology, 2006
- The Classification and Diagnosis of the Hypertensive Disorders of Pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)Hypertension in Pregnancy, 2001
- Glycosylated Hemoglobin in Insulin-Dependent Diabetes Mellitus Related to PreeclampsiaAmerican Journal of Perinatology, 1998